We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
Read MoreHide Full Article
Cardinal Health Inc. (CAH - Free Report) is well-poised for growth on the back of a diversified product portfolio, acquisition-driven strategy and a robust pharmaceutical segment. However, margin contraction remains a concern.
Shares of this Zacks Rank #3 (Hold) have gained 2.2% on a year-to-date basis against the industry’s decline of 8.5%. Further, the S&P 500 Index has declined 11.7% in the same time frame.
The company — with a market capitalization of $14.58 billion — is a nationwide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. It anticipates earnings to improve 4.6% over the next five years. Cardinal Health’s earnings yield is 10.1% compared with the industry’s 3.9%.
What’s Driving the Performance?
Cardinal Health’s Medical and Pharmaceutical offerings provide it with a competitive edge in the niche space. It offers industry expertise through an expanding portfolio of safe products.
The company pursues an acquisition-driven strategy and remains committed to investment in key growth businesses to gain market traction and bolster profits.
Cardinal Health’s Pharmaceutical segment is the second-largest pharmaceutical distributor in the United States. The segment’s products and services comprise pharmaceutical distribution, manufacturer and specialty solutions, and nuclear and pharmacy offerings. The segment’s strength is expected to drive its performance in the days ahead.
Image Source: Zacks Investment Research
In the second quarter of fiscal 2022, pharmaceutical revenues amounted to $41.38 billion, up 11% on a year-over-year basis. The performance reflects branded pharmaceutical sales growth from Pharmaceutical Distribution and Specialty Solutions customers.
On the fiscal first-quarter 2022 earnings call, the company said that it has been witnessing commercial momentum with Navista TS.
In November 2021, the company announced that its business — WaveMark Supply Management and Workflow Solutions — can now be implemented in clinical labs throughout the United States. Interestingly, WaveMark is among the first in the industry to improve clinical lab processes with the help of cutting-edge automation.
What’s Weighing on the Stock?
In the second quarter of fiscal 2022, gross profit fell 9% year over year to $1.62 billion. As a percentage of revenues, gross margin in the reported quarter was 3.6%, down 70 basis points (bps) on a year-over-year basis.
With respect to the Medical segment, revenues fell 5% to $4.09 billion due to the divestiture of the Cordis business. The company reported a profit of $50 million in the Medical segment, which plunged 79% from the year-ago quarter, primarily due to inflationary impacts and global supply chain restrictions in products and distribution. The deterioration highlights the timing of selling higher-cost personal protective equipment (PPE), including the net positive impact in the prior year, and to a smaller extent, the divestiture of the Cordis business.
Estimates Trend
For fiscal 2022, the Zacks Consensus Estimate for revenues is pegged at $177.27 billion, indicating an improvement of 9.1% from the previous year’s reported number.
The same for adjusted earnings per share stands at $5.29, suggesting a decline of 5% from the year-ago reported figure.
Stocks to Consider
Some better-ranked stocks from the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Henry Schein, Inc. (HSIC - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20%. The company currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 16.2%. AMN’s earnings yield of 8.8% compares favorably with the industry’s 0.3%.
Henry Schein beat earnings estimates in each of the trailing four quarters, the average surprise being 25.5%. The company currently sports a Zacks Rank #2 (Buy).
Henry Schein’s long-term earnings growth rate is estimated at 11.8%. HSIC’s earnings yield of 5.6% compares favorably with the industry’s 4.1%.
McKesson surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20.6%. The company currently carries a Zacks Rank #2.
McKesson’s long-term earnings growth rate is estimated at 11.8%. MCK’s earnings yield of 8.8% compares favorably with the industry’s 4.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
Cardinal Health Inc. (CAH - Free Report) is well-poised for growth on the back of a diversified product portfolio, acquisition-driven strategy and a robust pharmaceutical segment. However, margin contraction remains a concern.
Shares of this Zacks Rank #3 (Hold) have gained 2.2% on a year-to-date basis against the industry’s decline of 8.5%. Further, the S&P 500 Index has declined 11.7% in the same time frame.
The company — with a market capitalization of $14.58 billion — is a nationwide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. It anticipates earnings to improve 4.6% over the next five years. Cardinal Health’s earnings yield is 10.1% compared with the industry’s 3.9%.
What’s Driving the Performance?
Cardinal Health’s Medical and Pharmaceutical offerings provide it with a competitive edge in the niche space. It offers industry expertise through an expanding portfolio of safe products.
The company pursues an acquisition-driven strategy and remains committed to investment in key growth businesses to gain market traction and bolster profits.
Cardinal Health’s Pharmaceutical segment is the second-largest pharmaceutical distributor in the United States. The segment’s products and services comprise pharmaceutical distribution, manufacturer and specialty solutions, and nuclear and pharmacy offerings. The segment’s strength is expected to drive its performance in the days ahead.
Image Source: Zacks Investment Research
In the second quarter of fiscal 2022, pharmaceutical revenues amounted to $41.38 billion, up 11% on a year-over-year basis. The performance reflects branded pharmaceutical sales growth from Pharmaceutical Distribution and Specialty Solutions customers.
On the fiscal first-quarter 2022 earnings call, the company said that it has been witnessing commercial momentum with Navista TS.
In November 2021, the company announced that its business — WaveMark Supply Management and Workflow Solutions — can now be implemented in clinical labs throughout the United States. Interestingly, WaveMark is among the first in the industry to improve clinical lab processes with the help of cutting-edge automation.
What’s Weighing on the Stock?
In the second quarter of fiscal 2022, gross profit fell 9% year over year to $1.62 billion. As a percentage of revenues, gross margin in the reported quarter was 3.6%, down 70 basis points (bps) on a year-over-year basis.
With respect to the Medical segment, revenues fell 5% to $4.09 billion due to the divestiture of the Cordis business. The company reported a profit of $50 million in the Medical segment, which plunged 79% from the year-ago quarter, primarily due to inflationary impacts and global supply chain restrictions in products and distribution. The deterioration highlights the timing of selling higher-cost personal protective equipment (PPE), including the net positive impact in the prior year, and to a smaller extent, the divestiture of the Cordis business.
Estimates Trend
For fiscal 2022, the Zacks Consensus Estimate for revenues is pegged at $177.27 billion, indicating an improvement of 9.1% from the previous year’s reported number.
The same for adjusted earnings per share stands at $5.29, suggesting a decline of 5% from the year-ago reported figure.
Stocks to Consider
Some better-ranked stocks from the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Henry Schein, Inc. (HSIC - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20%. The company currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 16.2%. AMN’s earnings yield of 8.8% compares favorably with the industry’s 0.3%.
Henry Schein beat earnings estimates in each of the trailing four quarters, the average surprise being 25.5%. The company currently sports a Zacks Rank #2 (Buy).
Henry Schein’s long-term earnings growth rate is estimated at 11.8%. HSIC’s earnings yield of 5.6% compares favorably with the industry’s 4.1%.
McKesson surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20.6%. The company currently carries a Zacks Rank #2.
McKesson’s long-term earnings growth rate is estimated at 11.8%. MCK’s earnings yield of 8.8% compares favorably with the industry’s 4.1%.